Mirum Pharmaceuticals Inc (MIRM)

$92.49 +0.65 (0.71%)
Market Cap 5.60B
Revenue (ttm) 521.31M
Net Income (ttm) -23.36M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4.48%
Debt to Equity Ratio 0.00
Volume 697,600
Avg Vol 962,616
Day's Range N/A - N/A
Shares Out 60.98M
Stochastic %K 17%
Beta 0.50
Analysts Strong Sell
Price Target $144.15

Company Profile

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercializat...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 667 4085
Address:
989 East Hillsdale Boulevard, Suite 300, Foster City, United States
Jonita
Jonita Jun. 4 at 2:59 PM
$MIRM in in
0 · Reply
Engrdon
Engrdon Jun. 2 at 7:39 PM
$MIRM Why the sell-off? My two cents: Last weekend’s EASL data looked strong. Could just be profit-taking after a run-up or a pullback after good news while investors digest the large amount of new EASL data. MIRM is now a successful commercial-stage biotech, and if upcoming catalysts continue to go well, it could become an even stronger growth company over the next 6–18 months.
0 · Reply
Waytobe360
Waytobe360 Jun. 2 at 5:09 PM
$MIRM out at $94 with a 77% win. Took months but we hit the target. From july 25 to june 26.
0 · Reply
wowster
wowster Jun. 2 at 2:11 PM
$MIRM why the selloff last few days?
1 · Reply
LMXPERTEN
LMXPERTEN Jun. 1 at 4:24 PM
$MIRM thank you!🙏😍
0 · Reply
AlertsAndNews
AlertsAndNews May. 30 at 4:41 PM
$MIRM Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026 "Today announced new data from its rare liver disease programs. Late-breaking results from the Phase 2b VISTAS study of volixibat in PSC and Phase 2b AZURE-1 study of brelovitug in HDV"
0 · Reply
SuperGreenToday
SuperGreenToday May. 29 at 3:58 AM
$MIRM Share Price: $99.55 Contract Selected: Dec 18, 2026 $100 Calls Buy Zone: $15.72 – $19.43 Target Zone: $25.00 – $30.55 Potential Upside: 50% ROI Time to Expiration: 203 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MarketBeat
MarketBeat May. 27 at 11:09 AM
https://marketbeat.com/a/8678270/ $MIRM Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance
0 · Reply
LMXPERTEN
LMXPERTEN May. 21 at 11:09 PM
$MIRM another round another swing trade 😍
0 · Reply
cammy2
cammy2 May. 20 at 7:01 PM
$MIRM kinda getting sick of this one
0 · Reply
Latest News on MIRM
Incyte, Mirum to present Phase 2 results from PROGRESS study at ENDO 2026

2026-06-04T12:21:26.000Z - 16 hours ago

Incyte, Mirum to present Phase 2 results from PROGRESS study at ENDO 2026

INCY

Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026

Jun 4, 2026, 8:05 AM EDT - 16 hours ago

Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026

Mirum Pharmaceuticals initiated with a Buy at Citi

2026-06-02T10:20:40.000Z - 2 days ago

Mirum Pharmaceuticals initiated with a Buy at Citi

Mirum announces new data from its rare liver disease programs at EASL

2026-05-31T13:40:06.000Z - 4 days ago

Mirum announces new data from its rare liver disease programs at EASL

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

May 30, 2026, 12:00 PM EDT - 5 days ago

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026

May 21, 2026, 8:05 AM EDT - 14 days ago

Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026

Mirum Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 20, 2026, 1:35 PM EDT - 15 days ago

Mirum Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026

Mirum Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 19, 2026, 3:30 PM EDT - 16 days ago

Mirum Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

Mirum Pharmaceuticals initiated with an Outperform at Wolfe Research

2026-05-19T10:10:11.000Z - 16 days ago

Mirum Pharmaceuticals initiated with an Outperform at Wolfe Research

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 14, 2026, 4:01 PM EDT - 21 days ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes

May 12, 2026, 11:56 PM EDT - 23 days ago

Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes

Mirum Pharmaceuticals announces $600M convertible senior notes offering

2026-05-12T22:09:28.000Z - 23 days ago

Mirum Pharmaceuticals announces $600M convertible senior notes offering

Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

May 12, 2026, 4:01 PM EDT - 23 days ago

Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

May 12, 2026, 8:00 AM EDT - 23 days ago

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals price target raised to $165 from $164 at Raymond James

2026-05-07T20:31:03.000Z - 4 weeks ago

Mirum Pharmaceuticals price target raised to $165 from $164 at Raymond James

Mirum Pharmaceuticals price target raised to $145 from $125 at TD Cowen

2026-05-07T20:10:47.000Z - 4 weeks ago

Mirum Pharmaceuticals price target raised to $145 from $125 at TD Cowen

Mirum Pharmaceuticals price target raised to $142 from $128 at RBC Capital

2026-05-07T18:55:03.000Z - 4 weeks ago

Mirum Pharmaceuticals price target raised to $142 from $128 at RBC Capital

Mirum Pharmaceuticals price target raised to $129 from $112 at Baird

2026-05-07T15:47:29.000Z - 4 weeks ago

Mirum Pharmaceuticals price target raised to $129 from $112 at Baird

Mirum Pharmaceuticals price target raised to $136 from $130 at Stifel

2026-05-07T15:03:35.000Z - 4 weeks ago

Mirum Pharmaceuticals price target raised to $136 from $130 at Stifel

Mirum Pharmaceuticals price target raised to $138 from $135 at Evercore ISI

2026-05-07T13:46:12.000Z - 4 weeks ago

Mirum Pharmaceuticals price target raised to $138 from $135 at Evercore ISI

Mirum Pharmaceuticals price target raised to $185 from $175 at H.C. Wainwright

2026-05-07T13:42:02.000Z - 4 weeks ago

Mirum Pharmaceuticals price target raised to $185 from $175 at H.C. Wainwright

Mirum Pharmaceuticals reports Q1 EPS ($13.43), consensus (35c)

2026-05-07T01:51:02.000Z - 4 weeks ago

Mirum Pharmaceuticals reports Q1 EPS ($13.43), consensus (35c)

Mirum Pharmaceuticals Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 weeks ago

Mirum Pharmaceuticals Earnings Call Transcript: Q1 2026

Mirum Pharmaceuticals Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 weeks ago

Mirum Pharmaceuticals Earnings release: Q1 2026

Mirum Pharmaceuticals Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 weeks ago

Mirum Pharmaceuticals Quarterly report: Q1 2026

Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

May 6, 2026, 4:01 PM EDT - 4 weeks ago

Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Mirum Pharmaceuticals Slides: Corporate presentation

May 6, 2026, 7:00 AM EDT - 4 weeks ago

Mirum Pharmaceuticals Slides: Corporate presentation

Mirum Pharmaceuticals price target raised to $140 from $130 at Morgan Stanley

2026-05-05T01:20:37.000Z - 4 weeks ago

Mirum Pharmaceuticals price target raised to $140 from $130 at Morgan Stanley

Mirum's rare liver disease drug meets main goal in mid-stage study

May 4, 2026, 2:04 PM EDT - 4 weeks ago

Mirum's rare liver disease drug meets main goal in mid-stage study

Mirum Pharmaceuticals price target raised to $175 from $150 at H.C. Wainwright

2026-05-04T15:40:57.000Z - 4 weeks ago

Mirum Pharmaceuticals price target raised to $175 from $150 at H.C. Wainwright

Mirum announces primary endpoint met in VISTAS Phase 2b study of volixibat

2026-05-04T12:39:54.000Z - 4 weeks ago

Mirum announces primary endpoint met in VISTAS Phase 2b study of volixibat

Mirum Pharmaceuticals Transcript: Study result

May 4, 2026, 8:30 AM EDT - 4 weeks ago

Mirum Pharmaceuticals Transcript: Study result

Mirum Pharmaceuticals Slides: Study result

May 4, 2026, 8:30 AM EDT - 4 weeks ago

Mirum Pharmaceuticals Slides: Study result

Mirum Pharmaceuticals Press release: Study result

May 4, 2026, 8:30 AM EDT - 4 weeks ago

Mirum Pharmaceuticals Press release: Study result

Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis

May 4, 2026, 8:00 AM EDT - 4 weeks ago

Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026

May 3, 2026, 5:00 PM EDT - 4 weeks ago

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026

Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026

Apr 29, 2026, 4:01 PM EDT - 5 weeks ago

Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026

Mirum Pharmaceuticals price target raised to $130 from $125 at Stifel

2026-04-29T11:26:51.000Z - 5 weeks ago

Mirum Pharmaceuticals price target raised to $130 from $125 at Stifel

Mirum Pharmaceuticals price target raised to $112 from $95 at Baird

2026-04-28T11:23:29.000Z - 5 weeks ago

Mirum Pharmaceuticals price target raised to $112 from $95 at Baird

Mirum Pharmaceuticals price target raised to $150 from $130 at H.C. Wainwright

2026-04-27T13:16:28.000Z - 5 weeks ago

Mirum Pharmaceuticals price target raised to $150 from $130 at H.C. Wainwright

Mirum announces primary endpoint met in Phase 2b portion of AZURE-1 study

2026-04-27T12:17:05.000Z - 5 weeks ago

Mirum announces primary endpoint met in Phase 2b portion of AZURE-1 study

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus

Mirum Pharmaceuticals Slides: Corporate presentation

Apr 27, 2026, 7:00 AM EDT - 5 weeks ago

Mirum Pharmaceuticals Slides: Corporate presentation

Mirum Pharmaceuticals Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 6 weeks ago

Mirum Pharmaceuticals Proxy statement: Proxy filing

Mirum Pharmaceuticals Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 6 weeks ago

Mirum Pharmaceuticals Proxy statement: Proxy filing

Egetis Appoints Tiago Nunes as Chief Medical Officer

Apr 9, 2026, 1:15 AM EDT - 2 months ago

Egetis Appoints Tiago Nunes as Chief Medical Officer

Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases

Mar 16, 2026, 8:00 AM EDT - 2 months ago

Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases

Mirum Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 10:00 AM EDT - 3 months ago

Mirum Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mirum Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 10:10 AM EDT - 3 months ago

Mirum Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026

Mirum Pharmaceuticals Slides: Corporate presentation

Mar 6, 2026, 6:00 AM EST - 3 months ago

Mirum Pharmaceuticals Slides: Corporate presentation

Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus

Mar 5, 2026, 8:00 AM EST - 3 months ago

Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus

Mirum Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 1:10 PM EST - 3 months ago

Mirum Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mirum Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 3 months ago

Mirum Pharmaceuticals Earnings Call Transcript: Q4 2025

Mirum Pharmaceuticals Annual report: Q4 2025

Feb 25, 2026, 4:30 PM EST - 3 months ago

Mirum Pharmaceuticals Annual report: Q4 2025

Mirum Pharmaceuticals Earnings release: Q4 2025

Feb 25, 2026, 4:30 PM EST - 3 months ago

Mirum Pharmaceuticals Earnings release: Q4 2025

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update

Feb 25, 2026, 4:01 PM EST - 3 months ago

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update

Mirum Pharmaceuticals Slides: Corporate presentation

Feb 25, 2026, 7:00 AM EST - 3 months ago

Mirum Pharmaceuticals Slides: Corporate presentation

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026

Feb 18, 2026, 4:01 PM EST - 3 months ago

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026

Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

Feb 5, 2026, 8:51 AM EST - 4 months ago

Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)

Feb 5, 2026, 8:00 AM EST - 4 months ago

Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)

Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

Jan 26, 2026, 8:00 AM EST - 4 months ago

Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

Mirum Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 2:15 PM EST - 5 months ago

Mirum Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum

Jan 12, 2026, 8:30 AM EST - 5 months ago

Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum

Mirum Pharmaceuticals Slides: Corporate presentation

Jan 12, 2026, 7:00 AM EST - 5 months ago

Mirum Pharmaceuticals Slides: Corporate presentation

Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals

Jan 9, 2026, 11:55 AM EST - 5 months ago

Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals

Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 4:01 PM EST - 5 months ago

Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX

Dec 19, 2025, 8:30 AM EST - 5 months ago

Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX

Mirum Pharmaceuticals Transcript: M&A Announcement

Dec 8, 2025, 8:30 AM EST - 6 months ago

Mirum Pharmaceuticals Transcript: M&A Announcement

Mirum Pharmaceuticals Press release: M&A Announcement

Dec 8, 2025, 8:30 AM EST - 6 months ago

Mirum Pharmaceuticals Press release: M&A Announcement

Mirum Pharmaceuticals Slides: M&A Announcement

Dec 8, 2025, 8:30 AM EST - 6 months ago

Mirum Pharmaceuticals Slides: M&A Announcement

Mirum Pharma to buy Bluejay Therapeutics for up to $820 million

Dec 8, 2025, 8:05 AM EST - 6 months ago

Mirum Pharma to buy Bluejay Therapeutics for up to $820 million

Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

Dec 8, 2025, 8:00 AM EST - 6 months ago

Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

Mirum Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 2:10 PM EST - 6 months ago

Mirum Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome

Dec 1, 2025, 8:10 AM EST - 6 months ago

Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome

Mirum Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 8:40 AM EST - 7 months ago

Mirum Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD's The Liver Meeting®

Nov 7, 2025, 8:10 AM EST - 7 months ago

Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD's The Liver Meeting®

Mirum Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

Mirum Pharmaceuticals Earnings Call Transcript: Q3 2025

Mirum Pharmaceuticals Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

Mirum Pharmaceuticals Quarterly report: Q3 2025

Mirum Pharmaceuticals Earnings release: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

Mirum Pharmaceuticals Earnings release: Q3 2025

Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 4, 2025, 4:01 PM EST - 7 months ago

Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Mirum Pharmaceuticals Slides: Corporate presentation

Nov 4, 2025, 4:00 PM EST - 7 months ago

Mirum Pharmaceuticals Slides: Corporate presentation

Mirum Pharmaceuticals Slides: Corporate Presentation

Nov 3, 2025, 6:00 PM EST - 7 months ago

Mirum Pharmaceuticals Slides: Corporate Presentation

Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

Oct 28, 2025, 4:02 PM EDT - 7 months ago

Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

Mirum Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 10, 2025, 10:00 AM EDT - 9 months ago

Mirum Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Mirum Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 8:30 AM EDT - 9 months ago

Mirum Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study

Sep 8, 2025, 8:00 AM EDT - 9 months ago

Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study

Mirum Pharmaceuticals Slides: Corporate presentation

Sep 8, 2025, 7:00 AM EDT - 9 months ago

Mirum Pharmaceuticals Slides: Corporate presentation

Mirum Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 3:20 PM EDT - 9 months ago

Mirum Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Mirum Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 10 months ago

Mirum Pharmaceuticals Earnings Call Transcript: Q2 2025

Mirum Pharmaceuticals Quarterly report: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 10 months ago

Mirum Pharmaceuticals Quarterly report: Q2 2025

Mirum Pharmaceuticals Earnings release: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 10 months ago

Mirum Pharmaceuticals Earnings release: Q2 2025

Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 4:01 PM EDT - 10 months ago

Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Mirum Pharmaceuticals Slides: Corporate Presentation

Aug 6, 2025, 4:00 PM EDT - 10 months ago

Mirum Pharmaceuticals Slides: Corporate Presentation

Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

Jul 30, 2025, 4:01 PM EDT - 11 months ago

Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

Mirum Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 21, 2025, 9:00 AM EDT - 1 year ago

Mirum Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2025

Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

May 19, 2025, 8:30 AM EDT - 1 year ago

Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

Volixibat Data from Mirum's VANTAGE PBC Study Showcased at EASL

May 9, 2025, 8:30 AM EDT - 1 year ago

Volixibat Data from Mirum's VANTAGE PBC Study Showcased at EASL

Mirum Pharmaceuticals Earnings Call Transcript: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Mirum Pharmaceuticals Earnings Call Transcript: Q1 2025

Mirum Pharmaceuticals Quarterly report: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Mirum Pharmaceuticals Quarterly report: Q1 2025

Mirum Pharmaceuticals Earnings release: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Mirum Pharmaceuticals Earnings release: Q1 2025

Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 4:01 PM EDT - 1 year ago

Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Mirum Pharmaceuticals Slides: Corporate Presentation

May 7, 2025, 7:00 AM EDT - 1 year ago

Mirum Pharmaceuticals Slides: Corporate Presentation

Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Apr 30, 2025, 8:30 AM EDT - 1 year ago

Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses

Apr 28, 2025, 8:30 AM EDT - 1 year ago

Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses

Mirum's LIVMARLI Now FDA Approved in Tablet Formulation

Apr 14, 2025, 8:30 AM EDT - 1 year ago

Mirum's LIVMARLI Now FDA Approved in Tablet Formulation

Mirum Pharmaceuticals Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Mirum Pharmaceuticals Proxy statement: Proxy Filing

Mirum Pharmaceuticals Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Mirum Pharmaceuticals Proxy statement: Proxy Filing

Mirum Pharmaceuticals Slides: Corporate presentation

Apr 14, 2025, 7:00 AM EDT - 1 year ago

Mirum Pharmaceuticals Slides: Corporate presentation

LIVMARLI Now Approved in Japan for ALGS and PFIC

Mar 27, 2025, 8:30 AM EDT - 1 year ago

LIVMARLI Now Approved in Japan for ALGS and PFIC

Mirum Pharmaceuticals Transcript: Leerink’s Global Healthcare Conference 2025

Mar 11, 2025, 10:40 AM EDT - 1 year ago

Mirum Pharmaceuticals Transcript: Leerink’s Global Healthcare Conference 2025

Mirum Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Mirum Pharmaceuticals Earnings Call Transcript: Q4 2024

Mirum Pharmaceuticals Annual report: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Mirum Pharmaceuticals Annual report: Q4 2024

Mirum Pharmaceuticals Earnings release: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Mirum Pharmaceuticals Earnings release: Q4 2024

Mirum Pharmaceuticals Slides: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Mirum Pharmaceuticals Slides: Q4 2024

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Feb 26, 2025, 4:01 PM EST - 1 year ago

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Mirum's CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

Feb 24, 2025, 8:30 AM EST - 1 year ago

Mirum's CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

US FDA approves Mirum Pharma's genetic disorder drug

Feb 21, 2025, 12:01 PM EST - 1 year ago

US FDA approves Mirum Pharma's genetic disorder drug

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025

Feb 19, 2025, 4:04 PM EST - 1 year ago

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025

Mirum Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 12:45 PM EST - 1 year ago

Mirum Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

Jan 13, 2025, 8:30 AM EST - 1 year ago

Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

Mirum Pharmaceuticals Slides: Corporate Presentation

Jan 12, 2025, 7:00 PM EST - 1 year ago

Mirum Pharmaceuticals Slides: Corporate Presentation

Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 4:04 PM EST - 1 year ago

Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Mirum Pharmaceuticals Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 3, 2024, 2:10 PM EST - 1 year ago

Mirum Pharmaceuticals Transcript: 7th Annual Evercore ISI HealthCONx Conference

Mirum Pharmaceuticals Slides: Corporate presentation

Dec 3, 2024, 7:00 AM EST - 1 year ago

Mirum Pharmaceuticals Slides: Corporate presentation

Mirum Pharmaceuticals Transcript: Stifel 2024 Healthcare Conference

Nov 19, 2024, 10:20 AM EST - 1 year ago

Mirum Pharmaceuticals Transcript: Stifel 2024 Healthcare Conference

Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver Meeting

Nov 14, 2024, 8:00 AM EST - 1 year ago

Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver Meeting

Mirum Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Mirum Pharmaceuticals Earnings Call Transcript: Q3 2024

Mirum Pharmaceuticals Earnings release: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Mirum Pharmaceuticals Earnings release: Q3 2024

Mirum Pharmaceuticals Quarterly report: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Mirum Pharmaceuticals Quarterly report: Q3 2024

Mirum Pharmaceuticals Slides: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Mirum Pharmaceuticals Slides: Q3 2024

Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 12, 2024, 8:00 AM EST - 1 year ago

Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Nov 4, 2024, 4:30 PM EST - 1 year ago

Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Jonita
Jonita Jun. 4 at 2:59 PM
$MIRM in in
0 · Reply
Engrdon
Engrdon Jun. 2 at 7:39 PM
$MIRM Why the sell-off? My two cents: Last weekend’s EASL data looked strong. Could just be profit-taking after a run-up or a pullback after good news while investors digest the large amount of new EASL data. MIRM is now a successful commercial-stage biotech, and if upcoming catalysts continue to go well, it could become an even stronger growth company over the next 6–18 months.
0 · Reply
Waytobe360
Waytobe360 Jun. 2 at 5:09 PM
$MIRM out at $94 with a 77% win. Took months but we hit the target. From july 25 to june 26.
0 · Reply
wowster
wowster Jun. 2 at 2:11 PM
$MIRM why the selloff last few days?
1 · Reply
LMXPERTEN
LMXPERTEN Jun. 1 at 4:24 PM
$MIRM thank you!🙏😍
0 · Reply
AlertsAndNews
AlertsAndNews May. 30 at 4:41 PM
$MIRM Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026 "Today announced new data from its rare liver disease programs. Late-breaking results from the Phase 2b VISTAS study of volixibat in PSC and Phase 2b AZURE-1 study of brelovitug in HDV"
0 · Reply
SuperGreenToday
SuperGreenToday May. 29 at 3:58 AM
$MIRM Share Price: $99.55 Contract Selected: Dec 18, 2026 $100 Calls Buy Zone: $15.72 – $19.43 Target Zone: $25.00 – $30.55 Potential Upside: 50% ROI Time to Expiration: 203 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MarketBeat
MarketBeat May. 27 at 11:09 AM
https://marketbeat.com/a/8678270/ $MIRM Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance
0 · Reply
LMXPERTEN
LMXPERTEN May. 21 at 11:09 PM
$MIRM another round another swing trade 😍
0 · Reply
cammy2
cammy2 May. 20 at 7:01 PM
$MIRM kinda getting sick of this one
0 · Reply
Quantumup
Quantumup May. 19 at 10:29 AM
Wolfe Research🏁 $MIRM OP; $145 and said: IBAT There’s More Upside; Initiate at Outperform $IPSEY GNFTY $GSK GILD VIR Here's what Wolfe Research went on to say: https://x.com/Quantumup1/status/2056683042442252654?s=20
0 · Reply
LMXPERTEN
LMXPERTEN May. 18 at 7:37 PM
$MIRM THANK YOU thank youuuu 😄 free money!
0 · Reply
LMXPERTEN
LMXPERTEN May. 15 at 7:38 PM
$MIRM thank you! 🙏 again 😂
0 · Reply
Home_Skillet
Home_Skillet May. 14 at 4:47 PM
$MIRM still holding all shares strong may trim at 130 share price
0 · Reply
WAJeff
WAJeff May. 13 at 6:50 PM
$AXSM $JAZZ $MIRM $RVMD My favorite bios. What are yours? No sub-$10 ideas as a request
11 · Reply
WAJeff
WAJeff May. 13 at 3:36 PM
$MIRM $114.89 ath
0 · Reply
LMXPERTEN
LMXPERTEN May. 13 at 3:21 PM
$MIRM very strong holding. I sold at 113. 10%. Lets see then… not sure i will win this one 🧐😬
0 · Reply
LMXPERTEN
LMXPERTEN May. 13 at 1:36 PM
$MIRM ATH
0 · Reply
DonCorleone77
DonCorleone77 May. 12 at 8:06 PM
$MIRM Mirum Pharmaceuticals announces $600M convertible senior notes offering Mirum Pharmaceuticals announced its intention to offer, subject to market conditions and other factors, $600M aggregate principal amount of convertible senior notes due 2032 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
0 · Reply
LMXPERTEN
LMXPERTEN May. 12 at 4:41 PM
$MIRM dipping again and again 😍10% every time
0 · Reply
dgbio
dgbio May. 8 at 2:14 PM
$MIRM RBC raises 128 → 142, TD Cowen raises 125 → 145
0 · Reply
LMXPERTEN
LMXPERTEN May. 8 at 8:38 AM
$MIRM swinging 🕺 along, thank you anateurs 🙏
0 · Reply